Thank You!

The latest from Median

Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS

Median Technologies reports 2025 Q1 key financial indicators and provides an update on Q1 key operational achievements.

RELIVE pivotal study final results show that Median’s eyonis™ LCS SaMD met all key endpoints, demonstrating statistically significant performance, superior to state of the art, as well as device safety and efficacy. The results support the intended use for which eyonis™ LCS was developed, which was shared with the EU Notified Body and discussed with the FDA during the Q-submission phase.

Median will be exhibiting at the ESMO Congress on October 17 – 21 in Berlin. Happy to see you there at Messe Berlin!

Median will be exhibiting at the 2025 ASCO Annual Meeting, which will take place from May 30 to June 3 in Chicago, IL. Meet us at McCormick Place South, Hall A, Booth #11046 to learn more about our breakthrough imaging solutions and services for oncology clinical trials.

eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions

Median Technologies releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025.

Median will be exhibiting at the American Thoracic Society (ATS) International Conference in San Francisco, from May 18-21, 2025. Meet us at Moscone Center, Hall A B C, Booth #1662 to explore our eyonis™ LCS: our cutting-edge AI/ML-based CADe/CADx SaMD for Lung cancer screening.